CARSGEN-B's stock price surged 10.92% during intraday trading on Monday. The significant upward movement reflects a sharp increase in investor confidence following a major scientific development for the company.

The catalyst for the rally was the official publication of research results for the company's independently developed Zevorcabtagene Autoleucel injection in The Lancet, one of the world's most prestigious medical journals. This publication marks a notable breakthrough in the challenging field of solid tumor CAR-T cell therapy, an area considered a critical unmet medical need.

Market participants interpreted the recognition from such an authoritative journal as a strong validation of the company's scientific progress and competitive positioning within the global cell therapy landscape. Consequently, expectations for the future commercialization prospects of this core pipeline asset were substantially elevated, driving the positive re-rating of the stock.